Table 1 Patient characteristics
|  | Total (n = 636) | Patients with pathogenic variant (n = 113) |
|---|---|---|
Gender | ||
Female | 321 (50%) | 58 (51%) |
Male | 315 (50%) | 53 (49%) |
Age at diagnosis | ||
Median, range | 57 (16–82) | 54 (26–77) |
History of prior cancera | 103 (16%) | 24 (22%) |
Tumor type | ||
Colorectal cancer | 141 (22%) | 27 (24%) |
Breast cancer | 85 (13%) | 16 (14%) |
Bile duct cancer | 47 (7%) | 8 (7%) |
Pancreatic cancer | 43 (7%) | 7 (6%) |
NSCLC | 33 (5%) | 4 (4%) |
Prostate cancer | 26 (4%) | 3 (3%) |
Ovarian cancer | 23 (4%) | 7 (5%) |
Urothelial cancer | 20 (3%) | 5 (4%) |
Gastric cancer | 20 (3%) | 1 (1%) |
Cervical cancer | 18 (3%) | 1 (1%) |
Others | 17 (3%) | 1 (1%) |
Cancer of unknown primary origin (CUP) | 16 (3%) | 4 (4%) |
Sarcoma | 14 (2%) | 3 (3%) |
Head and neck cancer | 14 (2%) | 2 (2%) |
Neuroendocrine cancer | 13 (2%) | 1 (1%) |
Malignant Mesothelioma | 12 (2%) | 7 (6%) |
Melanoma | 12 (2%) | 2 (2%) |
Esophageal cancer | 11 (2%) | 2 (2%) |
SCLC | 11 (2%) | 0 |
Hepatocellular cancer | 10 (2%) | 2 (2%) |
Adrenocortical cancer | 8 (1%) | 0 |
Endometrial cancer | 8 (1%) | 1 (1%) |
Thymoma | 8 (1%) | 1 (1%) |
Renal cell carcinoma | 6 (1%) | 2 (2%) |
Adenoid cystic carcinoma (salivary gland) | 5 (1%) | 1 (1%) |
Myoepithelial carcinoma | 4 (0.5%) | 0 |
Glioblastoma | 4 (0.5%) | 0 |
Anogenital cancer | 3 (0.5%) | 0 |
Germ cell cancer | 2 (0.5%) | 0 |
Vulvovaginal cancer | 2 (0.5%) | 1 (1%) |
